Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases

T Ikeda, A Nishida, M Yamano, I Kimura - Pharmacology & therapeutics, 2022 - Elsevier
Dysbiosis is associated with various diseases. The composition and diversity of gut
microbiota affect host physiology through the production of bioactive metabolites. Short …

Functional and phenotypic diversity of microglia: implication for microglia-based therapies for Alzheimer's disease

YJ Xu, NPB Au, CHE Ma - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is a progressive neurodegenerative disease and is closely
associated with the accumulation of β-amyloid (Aβ) and neurofibrillary tangles (NFTs). Apart …

Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's disease

AP Tsai, C Dong, PBC Lin, AL Oblak, GV Di Prisco… - Immunity, 2023 - cell.com
Genetic association studies have demonstrated the critical involvement of the microglial
immune response in Alzheimer's disease (AD) pathogenesis. Phospholipase C-gamma-2 …

Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation

C Zhao, H Wang, Y Liu, L Cheng, B Wang, X Tian, H Fu… - Molecular Cell, 2023 - cell.com
Summary Hydroxycarboxylic acid receptor 2 (HCAR2), modulated by endogenous ketone
body β-hydroxybutyrate and exogenous niacin, is a promising therapeutic target for …

Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

B Yulug, O Altay, X Li, L Hanoglu, S Cankaya… - Translational …, 2023 - Springer
Background Alzheimer's disease (AD) is associated with metabolic abnormalities linked to
critical elements of neurodegeneration. We recently administered combined metabolic …

Development of a three-dimensional organoid model to explore early retinal phenotypes associated with Alzheimer's disease

SS Lavekar, J Harkin, M Hernandez, C Gomes… - Scientific Reports, 2023 - nature.com
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the
accumulation of Aβ plaques and neurofibrillary tangles, resulting in synaptic loss and …

Structural insights into the human niacin receptor HCA2-Gi signalling complex

Y Yang, HJ Kang, R Gao, J Wang, GW Han… - Nature …, 2023 - nature.com
The hydroxycarboxylic acid receptor 2 (HCA2) agonist niacin has been used as treatment for
dyslipidemia for several decades albeit with skin flushing as a common side-effect in treated …

Revisiting the role of vitamins and minerals in Alzheimer's disease

H Shah, F Dehghani, M Ramezan, RB Gannaban… - Antioxidants, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common type of dementia that affects millions of
individuals worldwide. It is an irreversible neurodegenerative disorder that is characterized …

Comprehensive review of nutraceuticals against cognitive decline associated with Alzheimer's disease

EE Reza-Zaldívar, DA Jacobo-Velázquez - ACS omega, 2023 - ACS Publications
Nowadays, nutraceuticals are being incorporated into functional foods or used as
supplements with nonpharmacological approaches in the prevention and management of …

[HTML][HTML] The promise of niacin in neurology

E Wuerch, GR Urgoiti, VW Yong - Neurotherapeutics, 2023 - Elsevier
Niacin (vitamin B3) is an essential nutrient that treats pellagra, and prior to the advent of
statins, niacin was commonly used to counter dyslipidemia. Recent evidence has posited …